Fig. 5

Combining 4-miRNA with CA-125 for R0 and non-R0 patients categorization in the validation set A–B: The ROC curves of A 4-miRNA panel, CA-125, CA-153, CA-199, and B 4-miRNA combined with CA-125 for detecting residual disease in the validation set (R0, n = 67; non-R0, n = 87). Maximum classification accuracy was labeled by the red circle. C: The 2-dimensional classified plot of the 4-miRNA panel score (y-axis) and serum log10(CA-125) level (x-axis) for all subjects in the discovery and validation sets (n = 184). The horizontal and vertical dashed lines represented the classification threshold of the 4-miRNA panel (1.422) and CA-125 (600 U/ml), respectively. The misclassified cases via 4-miRNA panel or CA-125 were marked with a red point (n = 27) or a blue circle (n = 59), respectively. D: The 2-dimensional classified plot of the prediction model combining 4-miRNA with CA-125 for all subjects in the discovery and validation sets (n = 184). The horizontal dashed line was the classification threshold (1.483) of the combined model. The false-positive and false-negative cases were in red (n = 16). E: The decision curve analysis (DCA) plot of three models (CA-125, 4-miRNA, 4-miRNA combined with CA-125) (n = 184). F: The P value list of differentially expressed 4-miRNA in our panel and public datasets(GSE113486, GSE94533). Red marked up-regulated miRNAs and blue marked down-regulated miRNAs. miRNA. microRNA; ROC receiver operating characteristic curve, R0, advanced ovarian cancer with no residual disease, non-R0 advanced ovarian cancer with any residual disease; *P < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001